Alcon

Unity VCS And LumiThera Will Drive Global Eye Care Transformation

AnalystHighTarget

Not Invested

Consensus Narrative from 15 Analysts

Published

31 Aug 25

AnalystHighTarget's Fair Value

CHF 98.45

37.8% undervalued

10 Sep

CHF 61.28

-25.7%

-2.2%

-25.7%

-2.2%

You can edit this narrative until Aug 31 9:32 PM. Then, changes will post as Updates.

Author's Valuation

CHF 98.4

37.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CHF 98.45

37.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.47%

Medical Equipment revenue growth rate

0.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.66%

Calculation

US$2.06b

Earnings '28

33.88x

PE Ratio '28

US$69.75b

Market Cap '28

US$69.75b

Market Cap '28

493.80m

No. shares '28

US$141.26

Share Price '28

US$141.26 Share Price '28

Discounted to 2025 @ 4.67% p.a.

US$123.18

Fair Value '25

US$123.18 Fair Value '25

Converted to CHF @ 0.7991 USD/CHF Exchange Rate

CHF 98.44

Fair Value '25